UP AND UP MUCUS RELIEF DM- dextromethorphan hydrobromide, guaifenesin tablet, extended release Target Corporation

Target Corporation Mucus Relief DM Drug Facts

Active ingredients (in each extended-release tablet)

Dextromethorphan HBr 30 mg Guaifenesin 600 mg

Purposes

Cough suppressant

Expectorant

Uses

- helps loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive
- temporarily relieves:
- cough due to minor throat and bronchial irritation as may occur with the common cold or inhaled irritants
- the intensity of coughing
- the impulse to cough to help you get to sleep

Warnings

Do not use

- for children under 12 years of age
- if you are now taking a prescription monoamine oxidase inhibitor (MAOI) (certain drugs for depression, psychiatric or emotional conditions, or Parkinson's disease), or for 2 weeks after stopping the MAOI drug. If you do not know if your prescription drug contains an MAOI, ask a doctor or pharmacist before taking this product.

Ask a doctor before use if you have

- persistent or chronic cough such as occurs with smoking, asthma, chronic bronchitis, or emphysema
- cough accompanied by too much phlegm (mucus)

When using this product

do not use more than directed

Stop use and ask a doctor if

 cough lasts more than 7 days, comes back, or occurs with fever, rash, or persistent headache. These could be signs of a serious illness.

If pregnant or breast-feeding,

ask a health professional before use.

Keep out of reach of children.

In case of overdose, get medical help or contact a Poison Control Center right away. (1-800-222-1222)

Directions

- do not crush, chew, or break tablet
- take with a full glass of water
- this product can be administered without regard for timing of meals
- adults and children 12 years and older:
 - 1 or 2 tablets every 12 hours; not more than 4 tablets in 24 hours
- children under 12 years of age: do not use

Other information

- each tablet contains: magnesium 15 mg
- do not use if printed foil under cap is broken or missing.
- store between 20-25°C (68-77°F)

Inactive ingredients

carbomer homopolymer type B, copovidone, D&C yellow #10 aluminum lake, hypromellose, magnesium hydroxide, magnesium stearate, microcrystalline cellulose, silicon dioxide

Questions?

Call 1-888-547-7400

Principal Display Panel

Compare to active ingredients in Mucinex® DM mucus relief DM guaifenesin 600 mg dextromethorphan hydrobromide 30 mg extended-release tablets

expectorant and cough suppressant

controls cough

thins and loosens mucus

ACTUAL SIZE

12 HOUR

40 EXTENDED-RELEASE TABLETS

40 EXTENDED-RELEASE TABLETS



UP AND UP MUCUS RELIEF DM

dextromethorphan hydrobromide, guaifenesin tablet, extended release

Product Information

Product Type HUMAN OTC DRUG Item Code (Source) NDC:11673-716

Active Ingredient/Active Moiety			
Ingredient Name	Basis of Strength	Strength	
	DEXTROMETHORPHAN HYDROBROMIDE	30 mg	
GUAIFENESIN (UNII: 495W7451VQ) (GUAIFENESIN - UNII:495W7451VQ)	GUAIFENESIN	600 mg	

Inactive Ingredients		
Ingredient Name	Strength	
CARBOMER HOMOPOLYMER TYPE B (ALLYL PENTAERYTHRITOL OR ALLYL SUCROSE CROSSLINKED) (UNII: K6MOM3T5YL)		
COPOVIDONE K25-31 (UNII: D9C330MD8B)		
D&C YELLOW NO. 10 (UNII: 35SW5USQ3G)		
HYPROMELLOSE, UNSPECIFIED (UNII: 3NXW29V3WO)		
MAGNESIUM HYDROXIDE (UNII: NBZ3QY004S)		
MAGNESIUM STEARATE (UNII: 70097M6I30)		
MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)		
SILICON DIOXIDE (UNII: ETJ7Z6XBU4)		

Product Characteristics					
Color	YELLOW	Score	no score		
Shape	OVAL	Size	16mm		
Flavor		Imprint Code	L219;600		
Contains					

P	Packaging					
#	Item Code	Package Description	Marketing Start Date	Marketing End Date		
1	NDC:11673-716- 01	1 in 1 CARTON	07/15/2019			
1		20 in 1 BOTTLE; Type 0: Not a Combination Product				
2	NDC:11673-716- 49	1 in 1 CARTON	07/15/2019			
2		40 in 1 BOTTLE; Type 0: Not a Combination Product				

Marketing Information			
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA207602	07/15/2019	

Revised: 10/2022 Target Corporation